How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?

Answer from: Medical Oncologist at Academic Institution

I would treat such a patient the same way that I would any patient with residual TNBC after neoadjuvant chemotherapy and pembrolizumab, which depends to some extent upon the patient's stage at diagnosis and the extent of residual disease at surgery - in patients with residual disease after neoadjuva...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
On a similar note, I just saw a woman post op who ...

Medical Oncologist at Warren Alpert Medical School of Brown University
The low PR expression wouldn't dissuade me from tr...

Please select the option that best describes you:

How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Related Questions